Summit Therapeutics (SMMT) Q3 2024 earnings summary

Executive summary

• Ivonescimab demonstrated a 49% reduction in disease progression or death versus pembrolizumab in Phase III trials, with benefit across PD-L1 and histology subgroups and strong Phase II/III data in multiple tumor types.

• Enrollment completed for the global Phase III HARMONI trial in EGFR-mutated advanced NSCLC; topline data expected mid-2025; FDA granted Fast Track Designation.

• HARMONI-3 trial protocol amended to include both squamous and non-squamous metastatic NSCLC, expanding the addressable market and increasing sample size to ~1,080 patients.

• $235 million raised in private placement in September 2024, boosting cash reserves to $487 million and supporting clinical development and trial expansion.

• Encouraging Phase II data in triple-negative breast cancer, head and neck, colorectal, and perioperative NSCLC support broader clinical development.

Financial highlights

• Ended Q3 2024 with $487 million in cash, cash equivalents, and short-term investments, bolstered by $235 million private placement.

• Q3 2024 GAAP R&D expenses were $37.7 million; non-GAAP R&D expenses were $31.9 million.

• Q3 2024 GAAP G&A expenses were $20.4 million; non-GAAP G&A expenses were $6.8 million.

• Q3 2024 GAAP operating expenses: $58.1 million; non-GAAP: $38.7 million.

• Q3 2024 GAAP net loss: $56.3 million ($0.08/share); non-GAAP net loss: $36.9 million ($0.05/share).

Outlook and guidance

• Sufficient cash to fund planned and expanded ivonescimab trials through 2025.

• Topline data from the global HARMONI Phase III trial expected mid-2025; HARMONI-7 Phase III trial initiation planned for early 2025.

• Expansion of HARMONI-3 to include non-squamous patients and updated endpoints expected to accelerate enrollment and broaden market opportunity.

• Continued expansion of clinical development into additional tumor types based on positive Phase II data.

• Ongoing evaluation of additional financing options, including equity, debt, and strategic partnerships.